Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination Therapy
MLS is a key prognostic factor in mRCC patients treated with NIVO+IPI. A risk model incorporating MLS, KPS, and histology can aid in patient stratification and treatment decisions.
Authors
- Hideto Ueki (ORCID: https://orcid.org/0000-0002-7742-4528)
- Naoto Wakita (ORCID: https://orcid.org/0009-0007-1353-7789)
- Yukari Bando (ORCID: https://orcid.org/0000-0001-7736-1216)
- Takuto Hara (ORCID: https://orcid.org/0000-0003-4524-2815)
- Tomoaki Terakawa (ORCID: https://orcid.org/0000-0002-4447-6516)
- Yasuyoshi Okamura (ORCID: https://orcid.org/0000-0002-8466-3949)
- Koji Chiba (ORCID: https://orcid.org/0000-0001-5575-0667)
- Yoshie Mita
- Kotaro Suzuki (ORCID: https://orcid.org/0000-0003-4589-9251)
- Jun Teishima (ORCID: https://orcid.org/0000-0001-8429-1607)
- Hideaki Miyake
Institutions
- Kobe University (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1111/iju.70065
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04